Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mercatello

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Dermatology|April 1, 1997
CD4 monoclonal antibody administration in atopic dermatitisE Robinet, C Stamm, J F Nicolas, et al.
Annales Francaises D'Anesthesie Et De Reanimation|November 27, 1999
[The value of anesthesia consultation in relation to the single preanesthetic visit]M Blanc-Jouvan, A Mercatello, D Long, et al.
Kidney International|August 1, 1991
Acute renal failure with preserved renal plasma flow induced by cancer immunotherapyA Mercatello, A Hadj-Aïssa, S Négrier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 1, 1993
[Immunotherapy of metastatic kidney cancer]S Négrier, A Mercatello, B Coronel, et al.
British Journal of Cancer|May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinomaS Négrier, A Mercatello, M Bret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
The New England Journal of Medicine|May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'ImmunothérapieS Negrier, B Escudier, C Lasset, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancerM S Negrier, C N Pourreau, P A Palmer, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Dermatology|April 1, 1997
CD4 monoclonal antibody administration in atopic dermatitisE Robinet, C Stamm, J F Nicolas, et al.
Annales Francaises D'Anesthesie Et De Reanimation|November 27, 1999
[The value of anesthesia consultation in relation to the single preanesthetic visit]M Blanc-Jouvan, A Mercatello, D Long, et al.
Kidney International|August 1, 1991
Acute renal failure with preserved renal plasma flow induced by cancer immunotherapyA Mercatello, A Hadj-Aïssa, S Négrier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 1, 1993
[Immunotherapy of metastatic kidney cancer]S Négrier, A Mercatello, B Coronel, et al.
British Journal of Cancer|May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinomaS Négrier, A Mercatello, M Bret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
The New England Journal of Medicine|May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'ImmunothérapieS Negrier, B Escudier, C Lasset, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancerM S Negrier, C N Pourreau, P A Palmer, et al.
Pageof 6